AE Management – Medical News Asia

Role of netupitant/palonosetron in the management of Carboplatin-induced Nausea and Vomiting

13 December 2024/Enter your password to view comments./in Therapeutic Areas, Oncology, AE Management In Depth/by Reema Subramanian

There is no excerpt because this is a protected post.

MHK-FOS-2024019 Netupitant palonosetron in the Effective Management of Multiday Chemotherapy

Netupitant/palonosetron in the Effective Management of Multiday Chemotherapy-induced Nausea and Vomiting

20 September 2024/Enter your password to view comments./in Therapeutic Areas, Oncology, AE Management In Depth/by Reema Subramanian

There is no excerpt because this is a protected post.

Netupitant/palonosetron in the management of concurrent chemoradiotherapy-induced nausea and vomiting in head and neck cancer patient

9 September 2024/Enter your password to view comments./in Therapeutic Areas, Head and Neck Cancer, Oncology, AE Management In Depth/by Reema Subramanian

There is no excerpt because this is a protected post.

NEPA as an Effective Therapeutic Approach for Managing ADC-Induced Nausea and Vomiting

20 August 2024/Enter your password to view comments./in Breast Cancer, Therapeutic Areas, Oncology, AE Management In Depth/by Jessica LAU

There is no excerpt because this is a protected post.

MHK-FOS-2024019 Case Sharing interview 2 KV

Effective Management of Chemotherapy-Induced Nausea and Vomiting (CINV) in a Patient Receiving T-DXd for Triple-Positive Breast Cancer

11 July 2024/Enter your password to view comments./in Breast Cancer, Therapeutic Areas, Oncology, AE Management In Depth/by Jessica LAU

There is no excerpt because this is a protected post.

MHK-FOS-2024019 Case Sharing interview 1 KV

Managing Chemotherapy-Induced Nausea and Vomiting in Gastric Cancer Patients with NEPA and Reduced Dexamethasone

9 July 2024/in Therapeutic Areas, Gastrointestinal Cancer, Oncology, AE Management In Depth/by Jessica LAU

There is no excerpt because this is a protected post.

the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant-1

The evolving role of NK₁ in CINV management

16 April 2021/in Oncology, Chemotherapy, AE Management/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

8 December 2020/19 Comments/in Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Haematology, Head and Neck Cancer, Lung Cancer, Oncology, Melanoma & Skin Cancer, Immunotherapy, AE Management, irAE Management/by Stijn van den Borne, MSc

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

Filgrastim-aafi FDA approved as Filgrastim Biosimilar

20 July 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Oncology, AE Management/by scienterrific

On July 20, the FDA approved filgrastim-aafi (Nivestym®, Pfizer), as a biosimilar to filgrastim (Neupogen, Amgen). The label includes all indications of the reference product.

FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

6 June 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Oncology, AE Management/by scienterrific

FDA approved Fulphila (pegfilgrastim-jmdb, Mylan GmbH), a biosimilar of Neulasta (pegfilgrastim, Amgen, Inc.) to decrease the chance of infection due to febrile neutropenia in patients receiving myelosuppressive chemotherapy with clinically significant incidence of febrile neutropenia and with non-myeloid cancers.